Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma
NCT00598507
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
ZK-EPO
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
[object Object]